Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment
An untreated 66-year-old woman with chronic myelogenous leukaemia (CML) in the chronic phase was initially given imatinib mesylate, rapidly achieving a good cytogenetic response with treatment. However, acute promyelocytic leukaemia complicated by a disseminated intravascular coagulation occurred 9...
Gespeichert in:
| Veröffentlicht in: | Acta haematologica 2007-01, Vol.117 (4), p.191-196 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 196 |
|---|---|
| container_issue | 4 |
| container_start_page | 191 |
| container_title | Acta haematologica |
| container_volume | 117 |
| creator | Oku, Eijiro Imamura, Rie Nagata, Shuichiro Takata, Yuka Seki, Ritsuko Otsubo, Korenori Hashiguchi, Michitoshi Osaki, Koichi Yakushiji, Kazuaki Yoshimoto, Kohji Ogata, Hideaki Sata, Michio Okamura, Takashi |
| description | An untreated 66-year-old woman with chronic myelogenous leukaemia (CML) in the chronic phase was initially given imatinib mesylate, rapidly achieving a good cytogenetic response with treatment. However, acute promyelocytic leukaemia complicated by a disseminated intravascular coagulation occurred 9 months after beginning imatinib treatment. Promyelocytic crisis of CML was diagnosed by demonstration of both BCR/ABL and PML/RARα chimeric genes in leukaemic cells by karyotypic and fluorescence in situ hybridization analysis. Clonal evolution with addition of the PML/RARα translocation may have arisen in the early chronic phase of CML, with expansion of this clone during imatinib treatment. Promyelocytic crisis of CML is rare; furthermore, we know of no previous report of promyelocytic crisis occurring during treatment with imatinib. |
| doi_str_mv | 10.1159/000097920 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_17170522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70501937</sourcerecordid><originalsourceid>FETCH-LOGICAL-c303t-62ee9d5e550af08f06eb036f6ade5ada0ff6da3e9b476740b2bce2b692a42da13</originalsourceid><addsrcrecordid>eNpFkE1PwzAMhiMEYmNw4IyEckLiUEjSNiVHVA2YtAkOQ-JWua0zwvoxkvbQf0-mTsMXy_bjV_ZLyDVnD5zH6pH5UIkS7IRMeSR4oKQUp2Tq2zyI_WBCLpz78ZVIQnVOJjzhCYuFmJKvD9vWA1ZtMXSmoKk1zjjaapp-27bxndV-uMGm7R1dYr8FrA3Qsrem2dBFDZ1pTE5X6IYKOqRri9DV2HSX5ExD5fDqkGfk82W-Tt-C5fvrIn1eBkXIwi6QAlGVMcYxA82eNJOYs1BqCSXGUALTWpYQosqjRCYRy0VeoMilEhCJEng4I3ej7s62vz26LquNK7CqoEF_c-b_ZFyFiQfvR7CwrXMWdbazpgY7ZJxlexuzo42evT2I9nmN5T958M0DNyOwBbtBewTG9T_OLXdC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70501937</pqid></control><display><type>article</type><title>Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment</title><source>MEDLINE</source><source>Karger Journals</source><creator>Oku, Eijiro ; Imamura, Rie ; Nagata, Shuichiro ; Takata, Yuka ; Seki, Ritsuko ; Otsubo, Korenori ; Hashiguchi, Michitoshi ; Osaki, Koichi ; Yakushiji, Kazuaki ; Yoshimoto, Kohji ; Ogata, Hideaki ; Sata, Michio ; Okamura, Takashi</creator><creatorcontrib>Oku, Eijiro ; Imamura, Rie ; Nagata, Shuichiro ; Takata, Yuka ; Seki, Ritsuko ; Otsubo, Korenori ; Hashiguchi, Michitoshi ; Osaki, Koichi ; Yakushiji, Kazuaki ; Yoshimoto, Kohji ; Ogata, Hideaki ; Sata, Michio ; Okamura, Takashi</creatorcontrib><description>An untreated 66-year-old woman with chronic myelogenous leukaemia (CML) in the chronic phase was initially given imatinib mesylate, rapidly achieving a good cytogenetic response with treatment. However, acute promyelocytic leukaemia complicated by a disseminated intravascular coagulation occurred 9 months after beginning imatinib treatment. Promyelocytic crisis of CML was diagnosed by demonstration of both BCR/ABL and PML/RARα chimeric genes in leukaemic cells by karyotypic and fluorescence in situ hybridization analysis. Clonal evolution with addition of the PML/RARα translocation may have arisen in the early chronic phase of CML, with expansion of this clone during imatinib treatment. Promyelocytic crisis of CML is rare; furthermore, we know of no previous report of promyelocytic crisis occurring during treatment with imatinib.</description><identifier>ISSN: 0001-5792</identifier><identifier>EISSN: 1421-9662</identifier><identifier>DOI: 10.1159/000097920</identifier><identifier>PMID: 17170522</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Aged ; Antineoplastic Agents ; Benzamides ; Case Report ; Flow Cytometry ; Humans ; Imatinib Mesylate ; Immunophenotyping ; In Situ Hybridization, Fluorescence ; Karyotyping ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Male ; Piperazines - therapeutic use ; Pyrimidines - therapeutic use ; Reverse Transcriptase Polymerase Chain Reaction</subject><ispartof>Acta haematologica, 2007-01, Vol.117 (4), p.191-196</ispartof><rights>2007 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c303t-62ee9d5e550af08f06eb036f6ade5ada0ff6da3e9b476740b2bce2b692a42da13</citedby><cites>FETCH-LOGICAL-c303t-62ee9d5e550af08f06eb036f6ade5ada0ff6da3e9b476740b2bce2b692a42da13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17170522$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oku, Eijiro</creatorcontrib><creatorcontrib>Imamura, Rie</creatorcontrib><creatorcontrib>Nagata, Shuichiro</creatorcontrib><creatorcontrib>Takata, Yuka</creatorcontrib><creatorcontrib>Seki, Ritsuko</creatorcontrib><creatorcontrib>Otsubo, Korenori</creatorcontrib><creatorcontrib>Hashiguchi, Michitoshi</creatorcontrib><creatorcontrib>Osaki, Koichi</creatorcontrib><creatorcontrib>Yakushiji, Kazuaki</creatorcontrib><creatorcontrib>Yoshimoto, Kohji</creatorcontrib><creatorcontrib>Ogata, Hideaki</creatorcontrib><creatorcontrib>Sata, Michio</creatorcontrib><creatorcontrib>Okamura, Takashi</creatorcontrib><title>Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment</title><title>Acta haematologica</title><addtitle>Acta Haematol</addtitle><description>An untreated 66-year-old woman with chronic myelogenous leukaemia (CML) in the chronic phase was initially given imatinib mesylate, rapidly achieving a good cytogenetic response with treatment. However, acute promyelocytic leukaemia complicated by a disseminated intravascular coagulation occurred 9 months after beginning imatinib treatment. Promyelocytic crisis of CML was diagnosed by demonstration of both BCR/ABL and PML/RARα chimeric genes in leukaemic cells by karyotypic and fluorescence in situ hybridization analysis. Clonal evolution with addition of the PML/RARα translocation may have arisen in the early chronic phase of CML, with expansion of this clone during imatinib treatment. Promyelocytic crisis of CML is rare; furthermore, we know of no previous report of promyelocytic crisis occurring during treatment with imatinib.</description><subject>Aged</subject><subject>Antineoplastic Agents</subject><subject>Benzamides</subject><subject>Case Report</subject><subject>Flow Cytometry</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Immunophenotyping</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Karyotyping</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Male</subject><subject>Piperazines - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><issn>0001-5792</issn><issn>1421-9662</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1PwzAMhiMEYmNw4IyEckLiUEjSNiVHVA2YtAkOQ-JWua0zwvoxkvbQf0-mTsMXy_bjV_ZLyDVnD5zH6pH5UIkS7IRMeSR4oKQUp2Tq2zyI_WBCLpz78ZVIQnVOJjzhCYuFmJKvD9vWA1ZtMXSmoKk1zjjaapp-27bxndV-uMGm7R1dYr8FrA3Qsrem2dBFDZ1pTE5X6IYKOqRri9DV2HSX5ExD5fDqkGfk82W-Tt-C5fvrIn1eBkXIwi6QAlGVMcYxA82eNJOYs1BqCSXGUALTWpYQosqjRCYRy0VeoMilEhCJEng4I3ej7s62vz26LquNK7CqoEF_c-b_ZFyFiQfvR7CwrXMWdbazpgY7ZJxlexuzo42evT2I9nmN5T958M0DNyOwBbtBewTG9T_OLXdC</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Oku, Eijiro</creator><creator>Imamura, Rie</creator><creator>Nagata, Shuichiro</creator><creator>Takata, Yuka</creator><creator>Seki, Ritsuko</creator><creator>Otsubo, Korenori</creator><creator>Hashiguchi, Michitoshi</creator><creator>Osaki, Koichi</creator><creator>Yakushiji, Kazuaki</creator><creator>Yoshimoto, Kohji</creator><creator>Ogata, Hideaki</creator><creator>Sata, Michio</creator><creator>Okamura, Takashi</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment</title><author>Oku, Eijiro ; Imamura, Rie ; Nagata, Shuichiro ; Takata, Yuka ; Seki, Ritsuko ; Otsubo, Korenori ; Hashiguchi, Michitoshi ; Osaki, Koichi ; Yakushiji, Kazuaki ; Yoshimoto, Kohji ; Ogata, Hideaki ; Sata, Michio ; Okamura, Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c303t-62ee9d5e550af08f06eb036f6ade5ada0ff6da3e9b476740b2bce2b692a42da13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Antineoplastic Agents</topic><topic>Benzamides</topic><topic>Case Report</topic><topic>Flow Cytometry</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Immunophenotyping</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Karyotyping</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Male</topic><topic>Piperazines - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oku, Eijiro</creatorcontrib><creatorcontrib>Imamura, Rie</creatorcontrib><creatorcontrib>Nagata, Shuichiro</creatorcontrib><creatorcontrib>Takata, Yuka</creatorcontrib><creatorcontrib>Seki, Ritsuko</creatorcontrib><creatorcontrib>Otsubo, Korenori</creatorcontrib><creatorcontrib>Hashiguchi, Michitoshi</creatorcontrib><creatorcontrib>Osaki, Koichi</creatorcontrib><creatorcontrib>Yakushiji, Kazuaki</creatorcontrib><creatorcontrib>Yoshimoto, Kohji</creatorcontrib><creatorcontrib>Ogata, Hideaki</creatorcontrib><creatorcontrib>Sata, Michio</creatorcontrib><creatorcontrib>Okamura, Takashi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta haematologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oku, Eijiro</au><au>Imamura, Rie</au><au>Nagata, Shuichiro</au><au>Takata, Yuka</au><au>Seki, Ritsuko</au><au>Otsubo, Korenori</au><au>Hashiguchi, Michitoshi</au><au>Osaki, Koichi</au><au>Yakushiji, Kazuaki</au><au>Yoshimoto, Kohji</au><au>Ogata, Hideaki</au><au>Sata, Michio</au><au>Okamura, Takashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment</atitle><jtitle>Acta haematologica</jtitle><addtitle>Acta Haematol</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>117</volume><issue>4</issue><spage>191</spage><epage>196</epage><pages>191-196</pages><issn>0001-5792</issn><eissn>1421-9662</eissn><abstract>An untreated 66-year-old woman with chronic myelogenous leukaemia (CML) in the chronic phase was initially given imatinib mesylate, rapidly achieving a good cytogenetic response with treatment. However, acute promyelocytic leukaemia complicated by a disseminated intravascular coagulation occurred 9 months after beginning imatinib treatment. Promyelocytic crisis of CML was diagnosed by demonstration of both BCR/ABL and PML/RARα chimeric genes in leukaemic cells by karyotypic and fluorescence in situ hybridization analysis. Clonal evolution with addition of the PML/RARα translocation may have arisen in the early chronic phase of CML, with expansion of this clone during imatinib treatment. Promyelocytic crisis of CML is rare; furthermore, we know of no previous report of promyelocytic crisis occurring during treatment with imatinib.</abstract><cop>Basel, Switzerland</cop><pmid>17170522</pmid><doi>10.1159/000097920</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-5792 |
| ispartof | Acta haematologica, 2007-01, Vol.117 (4), p.191-196 |
| issn | 0001-5792 1421-9662 |
| language | eng |
| recordid | cdi_pubmed_primary_17170522 |
| source | MEDLINE; Karger Journals |
| subjects | Aged Antineoplastic Agents Benzamides Case Report Flow Cytometry Humans Imatinib Mesylate Immunophenotyping In Situ Hybridization, Fluorescence Karyotyping Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Male Piperazines - therapeutic use Pyrimidines - therapeutic use Reverse Transcriptase Polymerase Chain Reaction |
| title | Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T00%3A27%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Promyelocytic%20Crisis%20of%20Chronic%20Myelogenous%20Leukaemia%20during%20Imatinib%20Mesylate%20Treatment&rft.jtitle=Acta%20haematologica&rft.au=Oku,%20Eijiro&rft.date=2007-01-01&rft.volume=117&rft.issue=4&rft.spage=191&rft.epage=196&rft.pages=191-196&rft.issn=0001-5792&rft.eissn=1421-9662&rft_id=info:doi/10.1159/000097920&rft_dat=%3Cproquest_pubme%3E70501937%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70501937&rft_id=info:pmid/17170522&rfr_iscdi=true |